<DOC>
	<DOC>NCT01797081</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthus Rhytides).</brief_summary>
	<brief_title>BOTOX® in the Treatment of Crow's Feet Lines in Japan</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Moderate to severe Crow's Feet Lines Current or previous botulinum toxin treatment of any serotype Diagnosis of myasthenia gravis, EatonLambert syndrome, amyotrophic lateral sclerosis Facial laser or light treatment for cosmetic purposes, microdermabrasion, superficial peels, or topical retinoid therapy or hormone cream within 3 months Laser treatment or phototherapy of the face for medical purposes, blepharoplasty, browlift or related procedure, periorbital permanent makeup, or oral retinoid therapy within one year Mediumdepth or deep facial peels within 5 years Prior facial cosmetic surgery (e.g., prior periorbital surgery, facial lift, periorbital treatment with fillers, implantation or transplantation)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>